Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866423 · ClinicalTrials.gov registry record · Phase 2
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01866423 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 4 participants.
The verdict
NCT01866423, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG orteronel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-10-25 |
| Est. Completion | 2016-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866423
The ClinicalTrials.gov registry entry for NCT01866423 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01866423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866423 about?
NCT01866423 is a clinical study titled "Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01866423?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2013-10-25. Estimated completion is 2016-07-26.
What interventions are being tested in trial NCT01866423?
The interventions under investigation include: laboratory biomarker analysis (OTHER), orteronel (DRUG).
Who is sponsoring clinical trial NCT01866423?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.